Experienced in Chondrosarcoma

Heinrich Resch

Vienna, AT 
Experienced in Chondrosarcoma
Vienna, AT 
OverviewLocationsClinical Research

Overview

Heinrich Resch practices in Vienna, Austria. Mr. Resch is rated as an Experienced expert by MediFind in the treatment of Chondrosarcoma. His top areas of expertise are Postmenopausal Osteoporosis, Osteoporosis, Osteogenesis Imperfecta, and Hypophosphatasia (HPP).

His clinical research consists of co-authoring 60 peer reviewed articles and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 1 article in the study of Chondrosarcoma.

Gender
Male

Locations

Vienna, Austria

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

MicroRNAs Levels in Women With Postmenopausal Osteoporosis Under Antiresorptive or Osteoanabolic Treatment
MicroRNAs Levels in Women With Postmenopausal Osteoporosis Under Antiresorptive or Osteoanabolic Treatment
Enrollment Status: Completed
Publish Date: January 26, 2023
Intervention Type: Drug
Study Drugs: Denosumab, Teriparatide
Study Phase: Phase 4
Circulating miRNAs and Bone Microstructure in Adults With Hypophosphatasia
Circulating miRNAs and Bone Microstructure in Adults With Hypophosphatasia
Enrollment Status: Unknown
Publish Date: January 26, 2023
Intervention Type: Other
A Multicenter, Long-Term Extension Study of 104 Weeks, Including a Double-Blind, Placebo-Controlled 40-Week Randomized Withdrawal-Retreatment Period, to Evaluate the Maintenance of Treatment Effect of Ixekizumab (LY2439821) in Patients With Axial Spondyloarthritis
A Multicenter, Long-Term Extension Study of 104 Weeks, Including a Double-Blind, Placebo-Controlled 40-Week Randomized Withdrawal-Retreatment Period, to Evaluate the Maintenance of Treatment Effect of Ixekizumab (LY2439821) in Patients With Axial Spondyloarthritis
Enrollment Status: Completed
Publish Date: June 13, 2022
Intervention Type: Drug
Study Phase: Phase 3
View 2 Less Clinical Trials

60 Total Publications

The risk of femoral fracture is increased in patients with ischemic stroke and transient ischemic attack-a population-based observational secondary analysis of the Austrian stroke cohort.
The risk of femoral fracture is increased in patients with ischemic stroke and transient ischemic attack-a population-based observational secondary analysis of the Austrian stroke cohort.
Journal: International journal of stroke : official journal of the International Stroke Society
Published: July 23, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Resch's expertise for a condition
ConditionClose
View All 12 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile